Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears PET-Based Software for Centiloid Scaling of Amyloid Plaque Density
Now available with MIMneuro, the Centiloid scaling software provides automated quantitative assessment of amyloid plaque density, a key component of Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new Centiloid scaling software that enhances the assessment of amyloid plaque density on positron emission tomography (PET) and may facilitate the use of amyloid-targeted therapies for patients with Alzheimer’s disease.
Through the assessment of PET amyloid imaging, the Centiloid scaling software reportedly provides automated quantitative information on amyloid plaque density, according to MIM Software/GE HealthCare, the developer of the software. The company emphasized that amyloid plaque density is a key component of Alzheimer’s disease.
Through the assessment of PET amyloid imaging, the newly FDA-cleared Centiloid scaling software reportedly provides automated quantitative information on amyloid plaque density, according to MIM Software/GE HealthCare, the developer of the software. (Image courtesy of MIM Software/GE HealthCare.)
MIM Software said the Centiloid scaling software, now available with MIMneuro, also facilitates workflow efficiency by providing the quantitative assessments of amyloid plaque density alongside the PET images in a standardized report.
“Alzheimer’s is a far-reaching disease that has been a challenge for our society, patients, caregivers, and healthcare systems for decades,” explains Andrew Nelson, CEO of MIM Software, GE HealthCare. “Centiloid scaling with MIMneuro offers a standardized, quantitative metric to assist healthcare providers in confidently estimating amyloid plaque density, one key aspect of this debilitating disease. By increasing clinician confidence, we hope to ultimately expand patient access to cutting-edge, personalized care.”
Recent Videos
Related Content
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024Article
In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024Article
While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
